| Literature DB >> 26526097 |
Christopher B Rodell1, John W MacArthur2, Shauna M Dorsey1, Ryan J Wade1, Leo L Wang1, Y Joseph Woo3, Jason A Burdick1.
Abstract
Clinical percutaneous delivery of synthetically engineered hydrogels remains limited due to challenges posed by crosslinking kinetics - too fast leads to delivery failure, too slow limits material retention. To overcome this challenge, we exploit supramolecular assembly to localize hydrogels at the injection site and introduce subsequent covalent crosslinking to control final material properties. Supramolecular gels were designed through the separate pendant modifications of hyaluronic acid (HA) by the guest-host pair cyclodextrin and adamantane, enabling shear-thinning injection and high target site retention (>98%). Secondary covalent crosslinking occurred via addition of thiols and Michael-acceptors (i.e., methacrylates, acrylates, vinyl sulfones) on HA and increased hydrogel moduli (E=25.0±4.5kPa) and stability (>3.5 fold in vivo at 28 days). Application of the dual-crosslinking hydrogel to a myocardial infarct model showed improved outcomes relative to untreated and supramolecular hydrogel alone controls, demonstrating its potential in a range of applications where the precise delivery of hydrogels with tunable properties is desired.Entities:
Keywords: Michael-addition; hyaluronic acid; hydrogel; injectable; supramolecular assembly
Year: 2014 PMID: 26526097 PMCID: PMC4624407 DOI: 10.1002/adfm.201403550
Source DB: PubMed Journal: Adv Funct Mater ISSN: 1616-301X Impact factor: 18.808